BIIB · Biogen Inc
United States · RS rating 96 · As of 2026-11-03
| Price | 248.93 USD |
|---|---|
| 1-day change | -0.0% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 84 / 90 / 88 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 44 / 77 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -110.4% |
| Sales growth Q/Q | -10.1% |
| Distance from 52-week high | +1.9% |
| Market cap (USD) | $27.6B |